Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee
by Zacks Equity Research
bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
Will Corcept (CORT) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.
Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data
by Zacks Equity Research
Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -30% and 1.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Corcept (CORT) Up 9.6% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept's (CORT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Corcept Therapeutics' (CORT) fourth-quarter earnings and revenues lag estimates.
Corcept Therapeutics (CORT) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -39.13% and 0.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.